AstraZeneca’s Alexion posts 52 — week PREVAIL data backing once — weekly self — injected C5 inhibitor gefurulimab in gMG
AstraZeneca flagged new long-term trial results for gefurulimab in generalized myasthenia gravis, scheduled for presentation in late September 2026. Data from the PREVAIL Phase 3 open-label extension indicated sustained symptom control through 52 weeks in treated adults. Patients switching from placebo showed rapid imp